Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients
Launched by UNIVERSITY OF MINNESOTA · Apr 18, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effective a special screening and treatment plan is for preventing infections caused by a bacteria called Staphylococcus aureus (SA) in patients who are about to have surgery. The goal is to see if a 5-day treatment using a nasal ointment, body wash, and mouth rinse can help eliminate SA from patients before their surgery. The trial will compare four different methods for getting rid of this bacteria, including using the full treatment plan for some patients while others may receive different approaches.
To participate in this trial, individuals must be at least 18 years old, scheduled for certain types of surgeries at participating locations, and have their surgery planned at least 10 days after they enroll in the study. Participants will need to follow specific treatment steps before their surgery, and they'll be monitored to see if the bacteria is cleared from their bodies. This study is important as it aims to reduce the risk of infections that can happen after surgery, which can lead to longer hospital stays and additional treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Eligible participanst are outpatients in orthopedic, urology, neuro, otolaryngology, plastic and general surgery and OB/GYN clinics who are scheduled to undergo surgery at participating trial sites.
- • Anticipated surgery ≥ 10 days after the date of enrollment, to allow time for completion of baseline cultures and the decolonization protocol.
- • Age ≥ 18 years
- • Ability to complete the decolonization protocol pre-operatively as an outpatient.
- • No antibiotic therapy at the time of, or seven days prior to, baseline cultures, and no subsequent antibiotic therapy prior to the surgical procedure. Standard pre-op antibiotic prophylaxis given.
- • Patients are having skin incisions as part of their scheduled surgical procedure.
- Exclusion Criteria:
- • Inability to give informed consent
- • Surgery anticipated \<10 days after the baseline cultures
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Susan Kline, MD, MPH
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported